ClinicalTrials.gg
CompletedNCT00409006Updated Sep 9, 2010Results posted

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

A Phase 2 interventional study of Pemetrexed and Cisplatin in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
105th of 223
70 · median 64
Started
2007
with 11 others
Phase 2
128 of 227
12 open now
Registered
48th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 105th largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 128 in phase 2, and was the 48th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC). This study will be conducted in Asian patients who are classified as 'never smoker' since it is suggested that these patients are more likely to respond favorably to treatment with gefitinib.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic diagnosis non-small cell lung cancer (NSCLC) (Stage IIIB or IV)
  • Have not received any prior chemotherapy, molecular therapy, immunotherapy, biological therapy, or radiotherapy. Exception: palliative radiotherapy that is completed at least 4 weeks prior to study enrolment.
  • Have 'never smoked' (defined as having smoked \<100 cigarettes during his/her lifetime)
  • (ECOG) performance status 0 to 1

Exclusion criteria

Exclusion Criteria:

  • Concurrent administration of any other tumor therapy
  • Other co-existing
  • Pregnancy or breast feeding
  • Serious concomitant disorders
  • Inability or unwillingness to take folic acid or vitamin B12 supplementation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Pemetrexed/Cisplatin/Gefitinib

    Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Gefitinib

  • Experimental
    Pemetrexed/Cisplatin

    Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.

    Drug: Pemetrexed · Drug: Cisplatin

Interventions

  • 500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.

    Also known as: LY231514, Alimta

  • 75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity

  • 250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Defined as the time from randomization to the first observation of disease progression, or death due to any cause.

    Time frame: Baseline to first observation of disease progression or death, 12 weeks up to 31 months

Secondary outcomes

  1. Number of Participants With Tumor Response

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes not meeting above criteria. Responder is a participant exhibiting a best overall study response of CR or PR.

    Time frame: Baseline to measured response or death, 12 weeks up to 31 months

  2. Duration of Response for Responders

    The duration of a complete response (CR; the disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. A responder is a patient exhibiting a best overall study response of CR or PR.

    Time frame: Time of response to progressive disease or death, 12 weeks up to 31 months

  3. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. Median overall survival could not be estimated as most participants were living at the end of the study. 25 participants from each treatment group were censored. In place of this outcome measure, the percentage of participants who died during the study are provided in the Post-Hoc Analysis Outcome Measure: Percentage of Participants Who Died During the Study.

    Time frame: Baseline to date of death from any cause, 12 weeks up to 31 months

07

Results

Posted Sep 9, 2010
Limitations and caveats
Median overall survival cannot be estimated due to the high censor rate (25 participants per treatment group were censored). Most participants were still living at the end of the study.

Participant flow

Participant flow — Overall Study
MilestonePemetrexed/Cisplatin/GefitinibPemetrexed/Cisplatin
Started3931
Completed1919
Not completed2012
Withdrew: Death156
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject32
Withdrew: Physician decision12

Outcome measures

PrimaryProgression-Free Survival (PFS)

Defined as the time from randomization to the first observation of disease progression, or death due to any cause.

Time frame:
Baseline to first observation of disease progression or death, 12 weeks up to 31 months
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsPemetrexed/Cisplatin/GefitinibPemetrexed/Cisplatin
Progression-Free Survival (PFS)9.95 (5.85 to 16.49)6.83 (5.78 to 7.98)
Statistical analysis
  • Pemetrexed/Cisplatin/Gefitinib vs Pemetrexed/Cisplatin · Log Rank · p = 0.0618
SecondaryNumber of Participants With Tumor Response

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes not meeting above criteria. Responder is a participant exhibiting a best overall study response of CR or PR.

Time frame:
Baseline to measured response or death, 12 weeks up to 31 months
Reported as:
Number · Participants
Number of Participants With Tumor Response
ParticipantsPemetrexed/Cisplatin/GefitinibPemetrexed/Cisplatin
Number of Participants With Tumor Response18 (30.1 to 62.8)11 (19.2 to 54.6)
Statistical analysis
  • Pemetrexed/Cisplatin/Gefitinib vs Pemetrexed/Cisplatin · Regression, Logistic · p = 0.369Used the Wald Chi-squared statistic from a logistic regression analysis.
SecondaryDuration of Response for Responders

The duration of a complete response (CR; the disappearance of all target lesions) or partial response (PR; at least a 30% decrease in the sum of the longest diameter of target lesions) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. A responder is a patient exhibiting a best overall study response of CR or PR.

Time frame:
Time of response to progressive disease or death, 12 weeks up to 31 months
Reported as:
Median · Months
Duration of Response for Responders
MonthsPemetrexed/Cisplatin/GefitinibPemetrexed/Cisplatin
Duration of Response for Responders12.29 (8.51 to 15.31)4.14 (2.76 to 7.62)
Post-hocPercentage of Participants Who Died During the Study

This outcome measure takes the place of the outcome measure for Overall Survival, which could not be reported since the median value could not be calculated.

Time frame:
Baseline up to 31 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Died During the Study
Percentage of ParticipantsPemetrexed/Cisplatin/GefitinibPemetrexed/Cisplatin
Percentage of Participants Who Died During the Study35.919.4
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. Median overall survival could not be estimated as most participants were living at the end of the study. 25 participants from each treatment group were censored. In place of this outcome measure, the percentage of participants who died during the study are provided in the Post-Hoc Analysis Outcome Measure: Percentage of Participants Who Died During the Study.

Time frame:
Baseline to date of death from any cause, 12 weeks up to 31 months
Reported as:
Median · Months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed/Cisplatin/Gefitinib—6/39 (15.4%)38/39 (97.4%)
Pemetrexed/Cisplatin—3/31 (9.7%)31/31 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPemetrexed/Cisplatin/GefitinibPemetrexed/Cisplatin
NauseaGastrointestinal disorders1/391/31
VomitingGastrointestinal disorders1/391/31
InfectionInfections and infestations0/391/31
HeadacheNervous system disorders1/391/31
AsthmaRespiratory, thoracic and mediastinal disorders0/391/31
PneumonitisRespiratory, thoracic and mediastinal disorders0/391/31
DeathGeneral disorders1/390/31
PyrexiaGeneral disorders1/390/31
Acute tonsillitisInfections and infestations1/390/31
AnorexiaMetabolism and nutrition disorders1/390/31
Most frequent other events
Showing 10 of 69
Most frequent other events
EventPemetrexed/Cisplatin/GefitinibPemetrexed/Cisplatin
NauseaGastrointestinal disorders27/3920/31
VomitingGastrointestinal disorders19/3915/31
AnorexiaMetabolism and nutrition disorders19/3915/31
Neutrophil count decreasedInvestigations8/3913/31
PruritusSkin and subcutaneous tissue disorders14/395/31
Haemoglobin decreasedInvestigations8/3911/31
RashSkin and subcutaneous tissue disorders13/396/31
White blood cell count decreasedInvestigations6/398/31
DyspnoeaRespiratory, thoracic and mediastinal disorders6/398/31
DiarrhoeaGastrointestinal disorders10/393/31

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
Mean55.6 ± 8.4555.7 ± 12.4355.7 ± 10.32
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
Female302555
Male9615
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
East Asian393170
Region of Enrollment
Region of Enrollment(participants)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
Taiwan101121
China161430
Korea, Republic of13619
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Units on a scale)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
015924
1242246
History of Smoking
History of Smoking(Participants)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
Yes022
No392968
Basis of Diagnosis
Basis of Diagnosis(Participants)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
Histopathological302252
Cytological9918
Pathological Diagnosis
Pathological Diagnosis(Participants)Pemetrexed/Cisplatin/GefitinibPemetrexed/CisplatinTotal
Mixed Cell Carcinoma, Lung112
Adenocarcinoma302454
Carcinoma, Squamous Cell7411
Non-Small Cell Lung Carcinoma123

1 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fujian, 350014, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Qingdao, 266003, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 201900, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 137-701, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changhua, 500, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 100, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tao-Yuan, 333, Taiwan
09

References and documents

Publications

  • Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23. PubMed 22534669 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Aug 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2006
First posted
Dec 8, 2006
Start
Feb 2007
Primary completionActual
Aug 2009
CompletionActual
May 2010
Results first posted
Sep 9, 2010
Last update
Sep 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00409006
First posted
Dec 8, 2006
Start date
Feb 2007
Primary completion
Aug 2009
Completion
May 2010
Results posted
Sep 9, 2010
Last update
Sep 9, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion